C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/04 (2006.01) A61K 31/454 (2006.01) A61P 25/00 (2006.01) A61P 25/20 (2006.01) A61P 25/30 (2006.01) A61P 25/32 (2006.01) A61P 43/00 (2006.01)
Patent
CA 2679530
Disclosed is an ORL-1 receptor agonist having more excellent metabolic stability and stronger and higher selectivity than conventional compounds. The ORL-1 receptor agonist is therefore improved in bioavailability. Specifically disclosed is a compound represented by the following general formula (I). (In the formula, the symbols are as defined in the description.)
L'invention porte sur un agoniste des récepteurs ORL-1 pourvu d'une meilleure stabilité métabolique et d'une sélectivité plus forte et plus élevée que celle des composés classiques. L'agoniste des récepteurs ORL-1 présente par conséquent une biodisponibilité améliorée. De façon spécifique, l'invention porte sur un composé représenté par la formule générale (I). (I) (Dans la formule, les symboles sont tels que définis dans la description).
Hanano Tokushi
Horiuchi Hideki
Minoguchi Masanori
Nakano Masakazu
Ono Shin-Ichiro
Fetherstonhaugh & Co.
Mitsubishi Tanabe Pharma Corporation
LandOfFree
Benzimidazole compound and pharmaceutical use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazole compound and pharmaceutical use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazole compound and pharmaceutical use thereof will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1874563